Winter 2025 Breast Cancer Research Round Up

moderators · June 4

Have you been diagnosed with metastatic hormone receptor-positive breast cancer or DCIS? Dr. Kevin Fox discusses the latest research.

Apr 18, 2025

Can people diagnosed with metastatic hormone receptor-positive breast cancer avoid chemotherapy and take a CDK4/6 inhibitor instead? Do people diagnosed with DCIS need to have surgery? Will there soon be another oral selective estrogen degrader available?

Breastcancer.org medical advisor Dr. Kevin Fox explains the details of the studies and what they mean for you.

Listen to the episode to hear Dr. Fox discuss these studies:

Young-PEARL: Ibrance plus Aromasin, along with ovarian suppression, offers better progression-free survival than Xeloda for pre-menopausal women with metastatic hormone receptor-positive, HER2-negative breast cancer who had previously received tamoxifen.
PATINA: Adding Ibrance to standard-of-care first treatments for metastatic hormone receptor-positive, HER2-positive breast cancer increased progression-free survival by more than a year.
EMBER-3: Imlunestrant led to longer progression-free survival than standard therapy if the cancer had an ESR1 mutation among people with estrogen receptor-positive, HER2-negative advanced-stage breast cancer. Adding Verzenio to imlunestrant improved progression-free survival compared to imlunestrant alone, whether the cancer had an ESR1-mutation or not.
COMET: Can people with low-risk DCIS just be monitored instead of having surgery with or without radiation?